STOMACH CANCER DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that target HER2 are under developmental studies to treat advanced stomach cancer. For instance, pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to treat metastatic gastroesophageal junction or gastric cancer.

Market Dynamics

Increasing prevalence of stomach cancer worldwide is expected to boost the stomach cancer drugs market size. For instance, according to WCRF data of 2018, around one million cases of stomach cancer were diagnosed in 2018. Furthermore, increasing geriatric population is at a high risk of developing stomach cancer and men are more vulnerable to developing stomach cancer. For instance, according to the American Cancer Society (ACS) report in 2014, the average age of people diagnosed with stomach cancer is 68. As per the same source, six out of ten people diagnosed with stomach cancer annually are 65 or older, and stomach cancer is the fourth most common cancer in men.

However, the major challenge in the stomach cancer drugs market are the high expenses related to treatment of stomach cancer, which are not affordable to the middle to low income families in most countries. According to a data published in Oncotarget (impact journal) in 2017, the cost of stomach cancer drugs (considering Trastuzumab) can reach up to US$ 8,000 for four weeks and annually it can reach up to US$ 96,000.

Key features of the study

• This report provides in-depth analysis of the stomach cancer drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global stomach cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
• The global stomach cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for stomach cancer drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• Therapy Type Insights (Revenue, USD Mn, 2026 - 2033)
• Kinase Inhibitors
• Nucleoside Metabolic Inhibitors
• Anthracyclines
• VEGF Antibodies
• HER2 Receptor Antagonists
• Car T Cell Therapy Trastuzumab
• Trastuzumab
• Application Insights (Revenue, USD Mn, 2026 - 2033)
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
• Endoscopic Surgery
• Surgical Suite
• Dental Surgery
• Others
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• North Africa
• Central Africa
• South Africa
• Key Players Insights
• Pfizer Inc.
• Eli Lilly and Company
• GlaxoSmithKline Plc.
• Kuhnil Pharmaceutical Co. Ltd.
• Daiichi Sankyo Co. Ltd.
• Merck KGaA
• AstraZeneca Plc.
• Otsuka Holdings Co. Ltd.
• Sanofi S.A.
• F. Hoffmann-La Roche Ltd.
• Ono Pharmaceutical Co. Ltd.
• Bristol-Myers Squibb (BMS)
• Jiangsu HengRui Medicine Co. Ltd.
• Gilead Science Inc.
• Celgene Corporation
• Taiho Pharmaceutical
• Boston Biomedical Inc.
• Merck & Co.